| Pharmaceutical enterprises are a special industry,which is closely related to the people’s livelihood and health of a country.Therefore,pharmaceutical enterprises are often an important part of a country’s economy.At present,the Chinese medicine industry has been taking the "Internet plus" train on the fast track under the policy support,and the medical industry is developing rapidly,and the scale of the industry is also expanding rapidly.M&A,as an important way to expand the scale of enterprises in a short time,is gradually increasing in the pharmaceutical industry.However,after M&A,whether pharmaceutical enterprises can improve their performance through M&A,what factors affect their performance after M&A,and what kind of M&A is the most effective way to improve their performance are worth discussing.However,there is no clear conclusion on these issues.China Resources Sanjiu is a leading enterprise in China’s pharmaceutical industry.In recent years,China Resources Sanjiu is determined to reform and actively participate in mergers and acquisitions.This paper selects the case of China Resources Sanjiu’s merger and acquisition of Zhongyi pharmaceutical as the main object to analyze the impact of merger and acquisition on enterprise performance.At the beginning of writing this paper,it mainly expounds the research background,significance,research status of academic circles in the global field and the research object,content and method of this paper.Then it starts the theoretical basis of this paper,including the concept of M&A,the Balanced Scorecard and the relevant theories of enterprise M&A,and then analyzes the case of China Resources Sanjiu M&A of Zhongyi pharmaceutical,In depth analysis of its M&a motivation and M&a performance.The research methods used in this paper are event research method and balanced scorecard method.Through the analysis of the short-term and long-term performance of China Resources Sanjiu’s acquisition of Zhongyi pharmaceutical,it is found that M&A has created value for China Resources Sanjiu.Through the analysis of the merger and acquisition cases of China Resources Sanjiu,this paper analyzes the M&a performance of China Resources Sanjiu,and puts forward suggestions for its future development.At the same time,through the analysis of the merger and acquisition case of China Resources Sanjiu,it provides experience for other pharmaceutical enterprises that want to carry out merger and integration,so as to accelerate the development of the pharmaceutical industry. |
